Corporate Profile

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions.

We believe EG-1962, our lead product candidate, can fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. Read More

Stock Information

EDGE (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.01 (0.97%)
Data as of July 18, 2018 4:00 p.m. ET
Refresh quote

IR Contact

Gregory Gin

Upcoming Events

There are currently no events scheduled.
More >>


February 15, 2018
Download Documentation Investor Presentation – February 2018

Lastest News

June 27, 2018 - Edge Therapeutics Announces Updated Results from Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Read More
May 1, 2018 - Edge Therapeutics Reports First Quarter 2018 Financial Results
Read More
April 30, 2018 - Edge Therapeutics Announces Review of Strategic Alternatives
Read More

More >>

Data provided by Nasdaq. Minimum 15 minutes delayed.

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts